NASDAQ:JSPR Jasper Therapeutics Q2 2024 Earnings Report $3.34 -0.13 (-3.60%) As of 11:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Jasper Therapeutics EPS ResultsActual EPS-$0.97Consensus EPS -$1.09Beat/MissBeat by +$0.12One Year Ago EPSN/AJasper Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AJasper Therapeutics Announcement DetailsQuarterQ2 2024Date8/13/2024TimeBefore Market OpensConference Call DateTuesday, August 13, 2024Conference Call Time9:30AM ETUpcoming EarningsJasper Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Monday, August 11, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Jasper Therapeutics Earnings HeadlinesContrasting Jasper Therapeutics (NASDAQ:JSPR) & Climb Bio (NASDAQ:CLYM)July 15 at 4:53 AM | americanbankingnews.comHC Wainwright Issues Positive Outlook for JSPR EarningsJuly 15 at 2:15 AM | americanbankingnews.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 15 at 2:00 AM | Crypto Swap Profits (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 14 at 10:00 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 12 at 10:00 AM | prnewswire.comJSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law FirmJuly 11, 2025 | businesswire.comSee More Jasper Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jasper Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jasper Therapeutics and other key companies, straight to your email. Email Address About Jasper TherapeuticsJasper Therapeutics (NASDAQ:JSPR) is a clinical-stage biotechnology company dedicated to discovering and developing novel therapies that target the complement system for the prevention and treatment of rare diseases, organ transplant rejection and certain inflammatory conditions. Its lead product candidate, nomacopan, is an investigational, small‐protein dual inhibitor of complement component C5 and leukotriene B4, designed to address the underlying drivers of tissue damage in disorders such as paroxysmal nocturnal hemoglobinuria (PNH), bullous pemphigoid and cutaneous acute graft-versus-host disease. In addition to nomacopan, Jasper’s pipeline includes earlier-stage complement inhibitors aimed at improving transplant outcomes in kidney and other solid-organ recipients. Founded in 2015 as a spin-out from the University of Pennsylvania and the University of Washington, Jasper Therapeutics completed its initial public offering on the Nasdaq in 2018. The company has established strategic collaborations and license agreements to support global development and commercialization, leveraging partnerships with leading pharmaceutical firms to expand the reach of its complement‐modulating technology. Headquartered in Plymouth, Minnesota, Jasper conducts multi‐center clinical trials across North America, Europe and Australia. Jasper’s management team brings deep expertise in immunology, rare disease development and regulatory strategy. The company is led by a seasoned executive team and board of directors with decades of experience guiding small and mid‐sized biopharmaceutical enterprises through late‐stage clinical trials and toward potential commercialization. This leadership collective underscores Jasper’s commitment to advancing its pipeline and delivering transformative therapies for patients with high‐unmet medical needs.Written by Jeffrey Neal JohnsonView Jasper Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s Next Upcoming Earnings ASML (7/16/2025)Bank of America (7/16/2025)The Goldman Sachs Group (7/16/2025)Johnson & Johnson (7/16/2025)Kinder Morgan (7/16/2025)Morgan Stanley (7/16/2025)Progressive (7/16/2025)Prologis (7/16/2025)The PNC Financial Services Group (7/16/2025)Cintas (7/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
